- Home
- CLW vs CAPR Comparison
CLW vs CAPR Comparison
Compare CLW & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLW
- CAPR
- Stock Information
- Founded
- CLW 2005
- CAPR 2005
- Country
- CLW United States
- CAPR United States
- Employees
- CLW N/A
- CAPR N/A
- Industry
- CLW Paper
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLW Basic Materials
- CAPR Health Care
- Exchange
- CLW Nasdaq
- CAPR Nasdaq
- Market Cap
- CLW 338.8M
- CAPR 324.6M
- IPO Year
- CLW N/A
- CAPR N/A
- Fundamental
- Price
- CLW $17.32
- CAPR $6.72
- Analyst Decision
- CLW Strong Buy
- CAPR Strong Buy
- Analyst Count
- CLW 2
- CAPR 6
- Target Price
- CLW $30.00
- CAPR $23.00
- AVG Volume (30 Days)
- CLW 212.6K
- CAPR 1.1M
- Earning Date
- CLW 10-28-2025
- CAPR 11-11-2025
- Dividend Yield
- CLW N/A
- CAPR N/A
- EPS Growth
- CLW 875.72
- CAPR N/A
- EPS
- CLW 8.63
- CAPR N/A
- Revenue
- CLW $1,556,100,000.00
- CAPR $13,392,150.00
- Revenue This Year
- CLW $12.53
- CAPR N/A
- Revenue Next Year
- CLW $1.41
- CAPR $7,894.07
- P/E Ratio
- CLW $2.05
- CAPR N/A
- Revenue Growth
- CLW 23.00
- CAPR N/A
- 52 Week Low
- CLW $16.53
- CAPR $5.68
- 52 Week High
- CLW $33.57
- CAPR $22.90
- Technical
- Relative Strength Index (RSI)
- CLW 26.65
- CAPR 50.59
- Support Level
- CLW $16.53
- CAPR $6.13
- Resistance Level
- CLW $20.28
- CAPR $7.08
- Average True Range (ATR)
- CLW 0.79
- CAPR 0.38
- MACD
- CLW -0.10
- CAPR 0.02
- Stochastic Oscillator
- CLW 20.93
- CAPR 61.74
About CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.